In part 2 of this Exclusive Interview, Jon Odorico talks with Diabetes in Control during the ADA 2018 convention in Orlando about the results of the Viacyte stem cell trial as shared at a recent opinion leaders meeting.
Jon Odorico MD is Director of the Pancreas and Islet Cell Transplantation Programs and Professor in the Department of Surgery, Division of Organ Transplantation at the University of Wisconsin-Madison School of Medicine and Public Health.
Transcript of this video segment:
ViaCyte Stem Cell Trial
Odorico: A recent trial – first-in-human trial – was just completed by ViaCyte, which is a combination of a pancreatic progenitor cell population and a proprietary Encaptra macroencapsulation device. The results are very interesting. I think we learned a lot from that trial, although the results were not as robust as we would have hoped. First of all, I’m not affiliated with ViaCyte at all, I’m just reporting unpublished results that were presented at this Key Opinion Leaders Meeting. Secreted insulin was not observed in the blood of the patients. The sentinel devices were predictive of the larger devices in terms of the differentiation. But the number of differentiated insulin-expressing cells were not observed that were hoped to be observed in the histology in the devices at explant. However, there was no donor specific antibodies or autoantibodies detected in these recipients. There was some fibrotic capsule, so there are still some hurdles and the company is designing next phase trials with PEC-Direct trial.